WHITE PAPER: What s missing in women s health?
In July of last year, amidst stories in the press around HRT and contraception shortages, endometriosis going undiagnosed and unsafe medical devices being offered to women, we wrote an edition of MAGNIFI investigating the common theme between these stories – women were being let down when it came to their healthcare. Now, in 2021 for endometriosis awareness month, we are resharing this article and again asking the question: ‘what’s missing in women’s health?’
This white paper was initially published on the 9th July 2020, while the broader themes are still relevant, information on HRT stock issues may no longer apply.
Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According to the AUA risk stratification for non-muscle-invasive bladder cancer low risk disease is either a low-grade solitary Ta 3 cm tumor or PUNLMP. Conversely, there are several instances where low grade tumors are intermediate risk, including low grade Ta tumors that recur within 1 year of resection, solitary low grade Ta tumors 3cm, and multifocal low grade Ta tumors.
Laborie Medical Technologies, in Partnership with Urotronic Inc., Announces Completion of First Optilume® Procedure in Europe
In October 2020, LABORIE and Urotronic Inc. (Urotronic), entered into a multi-faceted, strategic partnership
1. Urotronic, a Minnesota-based medical device company, is currently conducting clinical trials in the United States to support regulatory approval of Optilume
®, a drug-coated balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH) and was recently granted CE Mark approval for use in urethral strictures in Europe
2.
Following the successful procedure, Dr. Georgi Tosev commented, In the last few decades, there has been stagnation in the treatment of urethral strictures. We re very excited to add this new treatment to our range of minimally invasive specialty procedures.